Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 24, 2020

View Archived Issues

Enrollment ongoing in phase II study of LX-9211 in postherpetic neuralgia

CDI-45205 selected as lead compound for development against coronaviruses

11C-PABA for dynamic PET to evaluate renal function: preclinical and first-in-human results

Safety and efficacy of once-weekly insulin icodec compared with once-daily glargine in phase II

First patients dosed in phase I/II study of SIIPL's COVID-19 vaccine candidate plus CpG-1018

Intranasal RECCE-327 and RECCE-529 demonstrate activity against SARS-CoV-2 virus in vivo

Topline data from pivotal phase II/III VALO study of Qtorin rapamycin in pachyonychia congenita

Indian researchers divulge new compounds for tuberculosis

University of Minnesota discloses BET inhibitors

Beijing Tide Pharmaceutical synthesizes new ATR kinase inhibitors

Shaanxi Panlong Pharmaceutical presents compounds for leukemia

Verseau Therapeutics describes new anti-SIGLEC9 antibodies

FDA approves international phase III study of carrimycin in patients with severe COVID-19

Health Canada authorizes Moderna's COVID-19 vaccine

FDA issues clinical hold on IND application for AdCOVID

A2 Biotherapeutics and Merck collaborate to develop novel allogeneic cell therapy

Adipocyte telomere length controls susceptibility to diabetes

First-in-human data presented for AMG-701 in relapsed/refractory multiple myeloma

FDA issues a Study May Proceed letter for phase Ib trial of CX-5461

Abionyx launches phase IIa study of CER-001 for prevention of AKI in septic patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...